Bulk Pharmaceutical API Sources for MESTRANOL; NORETHINDRONE

Bulk Pharmaceutical API Sources for MESTRANOL; NORETHINDRONE

Vendor	Vendor Homepage	Vendor Sku	API Url
ABI Chem		AC1L1Y84
BenchChem		B1200416
THE BioTek		bt-1540714
RR Scientific		R5270913

Bulk API Sources for Mestranol and Norethindrone

Last updated: February 19, 2026

This analysis identifies key bulk API manufacturers and suppliers for Mestranol and Norethindrone, critical components in oral contraceptive formulations. It outlines market dynamics, regulatory considerations, and potential supply chain risks for these active pharmaceutical ingredients.

What are the primary sources for Mestranol API?

Mestranol, a synthetic estrogen used in combination oral contraceptives, is manufactured by a limited number of specialized API producers. Sourcing typically involves established chemical synthesis pathways. Key considerations include API purity, compliance with Good Manufacturing Practices (GMP), and reliable supply chain logistics.

Major Manufacturers and Suppliers of Mestranol API:

• Amneal Pharmaceuticals: A significant player in the generic API market, Amneal offers Mestranol. Their production capabilities cater to large-scale pharmaceutical manufacturing.
• Ashok Organic Industries Ltd.: This Indian-based company is a known producer of steroid-based APIs, including Mestranol, serving global pharmaceutical markets.
• Hubei Gedian Pharma Ltd.: Located in China, Hubei Gedian Pharma is a supplier of various APIs, with Mestranol listed in their product portfolio. Their presence indicates a competitive landscape with Asian manufacturers.
• Sun Pharma Advanced Research Company Ltd.: While primarily focused on R&D, Sun Pharma’s API division is a potential source. Their integrated model may offer advantages in quality control and regulatory adherence.
• Yew Chung Pharmaceutical Co. Ltd.: This Taiwanese company is another established manufacturer of steroid APIs, including Mestranol, contributing to the global supply.

Geographic Distribution of Mestranol API Production:

The production of Mestranol API is concentrated in regions with strong chemical manufacturing infrastructure and established pharmaceutical supply chains.

Region	Key Countries
North America	United States
Asia	India, China, Taiwan

Regulatory Landscape for Mestranol API:

Mestranol API must comply with pharmacopeial standards, including the United States Pharmacopeia (USP) and European Pharmacopoeia (EP). Manufacturers must adhere to GMP regulations enforced by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Audits and site inspections are common.

What are the primary sources for Norethindrone API?

Norethindrone, a progestin used in contraceptives and hormone replacement therapy, is also a product of complex chemical synthesis. The market for Norethindrone API is more robust than Mestranol due to its broader therapeutic applications, though still dominated by a select group of manufacturers.

Major Manufacturers and Suppliers of Norethindrone API:

• Acme Formulation Pvt. Ltd.: An Indian API producer with a range of hormonal products, including Norethindrone, catering to diverse pharmaceutical needs.
• Amneal Pharmaceuticals: As with Mestranol, Amneal is a significant supplier of Norethindrone API, supporting generic drug formulations.
• Balaji Amines Ltd.: While known for other amines, Balaji Amines is involved in the production of certain steroid intermediates and APIs, potentially including Norethindrone.
• Cambrex Corporation: A global contract development and manufacturing organization (CDMO), Cambrex offers API development and manufacturing services, including for progestins like Norethindrone. Their expertise extends to complex synthesis and regulatory support.
• Capua Bio Services (formerly Capua Bioservices): While specialized in biologics, some CDMOs in this sector may have capabilities in complex small molecule synthesis, making them potential partners. However, direct API supply of Norethindrone is less commonly listed than for dedicated chemical API manufacturers.
• Eastman Chemical Company: Eastman has a significant presence in specialty chemicals and APIs, including hormonal compounds. Their scale and quality control are key strengths.
• Fidson Healthcare Plc: A Nigerian pharmaceutical company that also engages in API production, including Norethindrone, contributing to regional supply chains.
• Gharda Chemicals Limited: A prominent Indian agrochemical and pharmaceutical company, Gharda manufactures a range of APIs, with Norethindrone as part of its portfolio.
• Hubei Gedian Pharma Ltd.: Similar to Mestranol, this Chinese manufacturer lists Norethindrone among its offerings.
• Jubilant Pharmova Limited: A global integrated pharmaceutical company, Jubilant Pharmova produces APIs for various therapeutic areas, including steroidal APIs like Norethindrone.
• Laurus Labs Limited: An Indian research-driven pharmaceutical company, Laurus Labs manufactures APIs, and their capabilities in complex synthesis make them a potential supplier.
• Novasep: A French company offering synthesis and purification services for the pharmaceutical industry. They may produce Norethindrone on a custom synthesis basis or as a standard offering.
• Panacea Biotec Ltd.: Known for vaccines and pharmaceuticals, Panacea Biotec also has API manufacturing capabilities, potentially including Norethindrone.
• Pfizer CentreOne: As a division of Pfizer, Pfizer CentreOne acts as a CDMO, offering manufacturing services for APIs, which could encompass Norethindrone for clients.
• Rhodia (now Solvay): Solvay, through its acquisition of Rhodia, possesses chemical synthesis capabilities that could include Norethindrone production.
• Shilpa Medicare Limited: An Indian pharmaceutical company with strong API manufacturing expertise, Shilpa Medicare produces a variety of APIs, including those for hormonal products.
• Sun Pharma Advanced Research Company Ltd.: Similar to Mestranol, their API division is a potential source.
• Taj Pharmaceuticals Limited: Another Indian pharmaceutical company engaged in the manufacturing of APIs, including hormonal agents.
• Teva Pharmaceutical Industries Ltd.: A major global generic pharmaceutical company, Teva is a significant producer and consumer of APIs, including Norethindrone, for its own formulations and for supply to other manufacturers.
• Themis Medicare Ltd.: An Indian pharmaceutical company that manufactures APIs, potentially including Norethindrone.
• Wockhardt Limited: A global pharmaceutical and biotechnology company, Wockhardt has substantial API manufacturing operations, including for steroid-based drugs.
• Zydus Lifesciences Limited (formerly Cadila Healthcare): This Indian pharmaceutical giant has extensive API manufacturing capabilities, and Norethindrone is within their product scope.

Geographic Distribution of Norethindrone API Production:

Norethindrone API production is more geographically diverse than Mestranol, with a strong presence in India and China, alongside established players in North America and Europe.

Region	Key Countries
North America	United States
Europe	France
Asia	India, China, Taiwan
Africa	Nigeria

Regulatory Landscape for Norethindrone API:

Norethindrone API must meet stringent pharmacopeial standards (USP, EP). Manufacturers are subject to rigorous GMP compliance and regular inspections by regulatory bodies worldwide. The complexity of the molecule requires advanced synthesis and purification techniques, impacting the regulatory dossier.

What are the market dynamics and supply chain considerations?

The market for Mestranol and Norethindrone APIs is characterized by high barriers to entry due to complex synthesis, stringent quality requirements, and regulatory hurdles. The supply chain is global, with a significant portion of manufacturing concentrated in India and China, presenting both cost advantages and potential geopolitical or logistical risks.

Key Market Dynamics:

• Generic Dominance: The majority of Mestranol and Norethindrone APIs are supplied to the generic pharmaceutical market. This drives a focus on cost-effective production and large-scale manufacturing.
• CDMO Role: Contract Development and Manufacturing Organizations (CDMOs) play a crucial role, offering specialized synthesis expertise, scale-up capabilities, and regulatory support for companies that do not have in-house API manufacturing.
• Quality and Compliance: Pharmaceutical companies prioritize API suppliers with a proven track record of quality, regulatory compliance (FDA, EMA, WHO GMP), and robust quality management systems. Certificates of Analysis (CoA) and Drug Master Files (DMFs) are essential.
• Price Sensitivity: While quality is paramount, price remains a significant factor, particularly for large-volume generic drug manufacturers. Competition among suppliers, especially from Asia, influences pricing.
• Intellectual Property: While the primary patents for Mestranol and Norethindrone have long expired, process patents for novel synthesis routes or polymorphic forms can still be relevant.

Supply Chain Considerations:

• Geographic Concentration: Reliance on specific regions for API manufacturing creates vulnerabilities. Disruptions due to geopolitical events, natural disasters, trade disputes, or public health crises (e.g., pandemics) can impact supply.
• Lead Times: The synthesis and purification of complex APIs like Mestranol and Norethindrone involve multi-step processes, resulting in significant lead times from order placement to delivery. This necessitates proactive inventory management and long-term supply agreements.
• Raw Material Sourcing: The availability and pricing of key starting materials and intermediates used in the synthesis of these APIs can fluctuate, impacting production costs and availability.
• Transportation and Logistics: Global distribution requires efficient and compliant logistics to maintain API integrity during transit. Temperature control and security are critical.
• Dual Sourcing Strategy: To mitigate supply chain risks, pharmaceutical companies often pursue a dual or multi-sourcing strategy, engaging with several qualified API manufacturers to ensure continuity of supply.
• Regulatory Scrutiny: Increased regulatory scrutiny on API imports, including inspections of foreign manufacturing sites and stricter import alerts, necessitates robust supplier qualification processes.
• Sustainability: Growing emphasis on environmental, social, and governance (ESG) factors is leading some pharmaceutical companies to assess the sustainability practices of their API suppliers.

What are the future trends and challenges?

The landscape for bulk API sourcing of Mestranol and Norethindrone will continue to evolve, driven by regulatory shifts, technological advancements, and global market forces.

Future Trends:

• Continuous Manufacturing: The adoption of continuous manufacturing processes for API synthesis could offer benefits in terms of efficiency, quality control, and reduced waste, though implementation requires significant capital investment.
• Green Chemistry: Increased focus on developing more environmentally friendly synthesis routes, reducing solvent use, and minimizing hazardous by-products.
• Advanced Analytical Techniques: Utilization of sophisticated analytical methods for impurity profiling and characterization to meet ever-tightening regulatory standards.
• Supply Chain Resilience: Pharmaceutical companies will continue to invest in strategies to enhance supply chain resilience, including diversifying supplier bases, increasing inventory levels of critical APIs, and near-shoring or regionalizing manufacturing where feasible.
• Digitalization and Traceability: Implementation of digital technologies for better supply chain visibility, traceability, and data management, from raw material sourcing to final API delivery.

Challenges:

• Regulatory Harmonization: Discrepancies in regulatory requirements across different countries can create complexities for API manufacturers seeking to serve global markets.
• Cost Pressures: Continued pressure to reduce manufacturing costs while maintaining high quality standards remains a persistent challenge, especially in the competitive generic API market.
• Talent Shortage: The specialized expertise required for complex API synthesis and regulatory affairs can lead to a talent shortage, impacting manufacturing capacity and innovation.
• Geopolitical Instability: Global geopolitical tensions and trade policies can introduce uncertainty and disruption into international API supply chains.
• Cybersecurity: Protecting sensitive manufacturing data and intellectual property from cyber threats is increasingly critical for API manufacturers.

Table 1: Comparative Overview of API Sourcing

Feature	Mestranol API	Norethindrone API
Primary Use	Estrogen component in oral contraceptives	Progestin component in contraceptives, HRT
Market Size	Niche, primarily for specific OC formulations	Larger, broader therapeutic applications
Key Manufacturers	Limited, specialized steroid producers	More diverse, including larger CDMOs
Geographic Focus	North America, India, China, Taiwan	North America, Europe, India, China, Taiwan, Nigeria
Supply Chain Risk	Higher due to fewer suppliers	Moderate, due to broader supplier base
Regulatory Complexity	High, standard steroid API requirements	High, standard progestin API requirements
Cost Dynamics	Potentially higher per unit due to scale	Generally competitive due to volume and competition

Table 2: API Compliance and Documentation Requirements

Requirement	Description	Mestranol & Norethindrone
Good Manufacturing Practices	Adherence to current GMP standards (e.g., ICH Q7) as mandated by regulatory agencies (FDA, EMA, WHO).	Mandatory
Pharmacopeial Standards	Compliance with USP, EP, JP, or other relevant national pharmacopoeias for purity, assays, and impurity limits.	Mandatory
Drug Master File (DMF)	Submission of detailed information on the manufacturing process, facilities, and quality control to regulatory authorities.	Highly Recommended / Often Required
Certificate of Analysis (CoA)	Batch-specific documentation confirming the API meets all specified quality attributes.	Mandatory
Site Audits	Regular audits by pharmaceutical clients and regulatory agencies to verify GMP compliance.	Mandatory
Impurity Profiling	Comprehensive identification and quantification of process-related impurities and degradation products.	Critical
Stability Data	Data demonstrating the API's stability under defined storage conditions.	Required

Key Takeaways

• The sourcing of Mestranol and Norethindrone APIs is concentrated among a specialized group of global manufacturers, with India and China emerging as significant production hubs.
• Pharmaceutical companies must prioritize API suppliers with robust quality management systems, strong regulatory track records, and adherence to GMP standards.
• Supply chain resilience is a critical consideration, necessitating dual sourcing strategies and careful management of geopolitical and logistical risks associated with global manufacturing.
• The market is characterized by high barriers to entry, driven by complex synthesis requirements, stringent quality controls, and regulatory compliance demands.
• Future trends indicate a move towards more efficient manufacturing processes, green chemistry initiatives, and enhanced supply chain digitalization and traceability.

Frequently Asked Questions

What is the typical purity level required for Mestranol and Norethindrone APIs?

API purity requirements are dictated by pharmacopeial monographs (e.g., USP, EP) and specific regulatory filings for drug products. Generally, both Mestranol and Norethindrone APIs must achieve a purity of at least 98.0% to 99.5%, with strict limits on specific impurities, residual solvents, and heavy metals.

How does the regulatory status of an API supplier (e.g., FDA warning letters) impact sourcing decisions?

An FDA warning letter or other significant regulatory enforcement action against an API supplier immediately raises concerns about product quality and compliance. Pharmaceutical companies typically halt or suspend sourcing from such suppliers until the issues are resolved and verified through re-audits and regulatory clearance. This can lead to immediate supply disruptions and the need to qualify alternative sources.

What are the implications of a Drug Master File (DMF) for API sourcing?

A Drug Master File (DMF) provides confidential, detailed information about the manufacturing process, facilities, and quality controls of an API to regulatory agencies. Pharmaceutical companies referencing a DMF in their drug product applications can rely on the DMF holder to undergo regulatory review, simplifying their own submission process. A well-maintained DMF from a reputable supplier is a strong indicator of manufacturing quality and regulatory preparedness.

How do fluctuating raw material costs affect the pricing of Mestranol and Norethindrone APIs?

The synthesis of steroid APIs like Mestranol and Norethindrone relies on specific chemical intermediates and raw materials. Fluctuations in the prices of these upstream components, driven by supply-demand imbalances, geopolitical events, or production issues, directly impact the cost of producing the final API. Manufacturers typically pass these cost variations on to their pharmaceutical clients, necessitating ongoing price negotiation and risk assessment in supply agreements.

What is the typical shelf life of bulk Mestranol and Norethindrone APIs?

The typical shelf life for bulk Mestranol and Norethindrone APIs, when stored under recommended conditions (usually protected from light, moisture, and at controlled room temperature), is generally between two to five years. This is determined through extensive stability testing conducted by the API manufacturer as part of regulatory requirements.

---

[1] United States Pharmacopeia. (n.d.). USP-NF. Retrieved from https://www.usp.org/products/usp-nf [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia (Ph. Eur.). Retrieved from https://www.edqm.eu/en/european-pharmacopoeia-ph-eur-1 [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/guidelines